Lyell Immunopharma, Inc. (LYEL) stock
LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.67−0.98 (-6.69%)
Close on Nov 17, 2026Market cap $334.99MP/E –Yield –
Lyell Immunopharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Lyell Immunopharma's profit margin for the twelve months ending Jun 30, 2026 was -920285.2%. For fiscal 2025 it was -762355.6%, against -562285.2% the year before. The highest annual figure on record is -216.2% in fiscal 2022.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -762355.6% | −200070.3 |
| FY2024 | Dec 31, 2024 | -562285.2% | −381799.1 |
| FY2023 | Dec 31, 2023 | -180486.2% | −180269.9 |
| FY2022 | Dec 31, 2022 | -216.2% | +2133.2 |
| FY2021 | Dec 31, 2021 | -2349.5% | +286.8 |
| FY2020 | Dec 31, 2020 | -2636.3% | +17055.8 |
| FY2019 | Dec 31, 2019 | -19692.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1118875.0% | −585325.0 |
| Q1 FY2026 | Mar 31, 2026 | -1207650.0% | −462007.1 |
| Q4 FY2025 | Dec 31, 2025 | -2345383.3% | −600519.7 |
| Q3 FY2025 | Sep 30, 2025 | -258973.3% | −127846.9 |
| Q2 FY2025 | Jun 30, 2025 | -533550.0% | −181173.1 |
| Q1 FY2025 | Mar 31, 2025 | -745642.9% | +1276590.5 |
| Q4 FY2024 | Dec 31, 2024 | -1744863.6% | −1337709.8 |
| Q3 FY2024 | Sep 30, 2024 | -131126.5% | +72285.5 |
| Q2 FY2024 | Jun 30, 2024 | -352376.9% | −115747.3 |
| Q1 FY2024 | Mar 31, 2024 | -2022233.3% | −1919219.5 |
| Q4 FY2023 | Dec 31, 2023 | -407153.8% | −407136.5 |
| Q3 FY2023 | Sep 30, 2023 | -203412.0% | +2138388.0 |
| Q2 FY2023 | Jun 30, 2023 | -236629.6% | −236528.0 |
| Q1 FY2023 | Mar 31, 2023 | -103013.8% | −90691.2 |
| Q4 FY2022 | Dec 31, 2022 | -17.4% | +2948.8 |
| Q3 FY2022 | Sep 30, 2022 | -2341800.0% | −2340026.0 |
| Q2 FY2022 | Jun 30, 2022 | -101.6% | +2280.2 |
| Q1 FY2022 | Mar 31, 2022 | -12322.6% | −10071.4 |
| Q4 FY2021 | Dec 31, 2021 | -2966.2% | −1285.5 |
| Q3 FY2021 | Sep 30, 2021 | -1774.0% | +1564.2 |
| Q2 FY2021 | Jun 30, 2021 | -2381.8% | +846.4 |
| Q1 FY2021 | Mar 31, 2021 | -2251.2% | – |
| Q4 FY2020 | Dec 31, 2020 | -1680.7% | – |
| Q3 FY2020 | Sep 30, 2020 | -3338.2% | – |
| Q2 FY2020 | Jun 30, 2020 | -3228.2% | – |
See a number that looks wrong?